Entrada Therapeutics (TRDA) FY2025 10-K Risk Factors: 14 New, 12 Dropped

What the changes say

Entrada faces heavy regulatory scrutiny for its EEV-based muscular dystrophy candidates like ENTR-601-44.
New risks cover AI compliance, evolving tax laws, and U.S. political changes impacting operations.

What changed since the prior 10-K

New

NewRisks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates
currently generate no revenue from sales of any product, and we may never be able to develop or commercialize a marketable product
Entrada generates no product revenue and relies on FDA acceptance of INDs and successful preclinical GLP studies to start U.S. clinical trials.
NewRisks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates
ENTR-601-51, ENTR-801 and our partnered candidate VX-670. Delay or failure to advance programs or modalities, including ENTR-601-44, ENTR-601-45, ENTR-601-50, ENTR-601-51, ENTR-801 and VX-670 could adversely impact our business
The company's pipeline depends heavily on the success of Duchenne muscular dystrophy candidates like ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51.
NewRisks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates
trials and our therapeutic candidates may not have favorable results in clinical trials or receive regulatory approval on a timely basis, if at all
Preclinical success for therapeutic candidates like ENTR-601-51, ENTR-801, and VX-670 does not guarantee favorable clinical trial results.
NewRisks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates
the perception that they are receiving placebo. Difficulty enrolling or maintaining a sufficient number of patients to conduct our clinical trials, may require us to delay, limit or terminate clinical trials, any of which would harm our business, financial condition, results of operations and prospects
Novel EEV-based therapeutics present unknown human safety profiles and potential adverse side effects that could halt clinical development.
NewRisks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates
Neither we nor any current or future collaborator is permitted to market any of our therapeutic candidates in the United States until we receive approval from the FDA
Commercializing any therapeutic candidate requires formal FDA or foreign regulatory approval supported by substantial clinical data.
NewRisks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates
Although we have obtained rare pediatric disease designation for ENTR-601-44, we may not be eligible to receive a priority review voucher in the event the FDA determines we no longer meet the criteria for designation, revokes the designation or FDA approval does not occur prior to September 30, 2029
Entrada holds rare pediatric disease designation for ENTR-601-44 but may miss out on a priority review voucher if approval occurs after September 30, 2029.
NewRisks Related to Our Reliance on Third Parties
collaborations with us. Competing products, either developed by the collaborators or to which the collaborators have rights, may result in the withdrawal of support for our therapeutic candidates
Collaborators may develop competing products, reduce support, or terminate agreements prematurely, harming product development.
NewRisks Related to Commercialization of Our Therapeutic Candidates
from list prices and are challenging the prices charged for products. We cannot be sure that coverage will be available for any therapeutic candidate that we commercialize and, if coverage is available, the level of reimbursement
Government healthcare programs and private payors are enforcing mandatory price discounts, rebates, and stricter reimbursement challenges.
NewRisks Related to Our Business Operations and Industry
December 31, 2025, we had U.S. federal net operating loss carryforwards of approximately $178.3 million, and our ability to utilize those net operating loss carryforwards could be limited by an “ownership change” as described above, which could result in increased tax liability to us
As of December 31, 2025, Entrada had $178.3 million in U.S. federal net operating loss carryforwards subject to potential ownership change limitations.
NewRisks Related to Our Business Operations and Industry
The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business
Recent U.S. policy changes implemented by the Trump administration and Congress may adversely affect the company's business and trade relations.
NewRisks Related to Our Intellectual Property
process personal sensitive data, conduct data protection assessments, transfer personal data to affiliates, and respond to consumer rights requests
New state privacy laws such as Washington's My Health My Data Act increase compliance costs and potential liability for processing health data.
NewRisks Related to Our Intellectual Property
been successful at curtailing state action on AI regulation, contributing to a complicated legislative patchwork, which may be litigated in state and federal courts
The rapid evolution of artificial intelligence creates complex regulatory standards, vendor compliance risks, and intellectual property challenges.
NewRisks Related to Ownership of Our Common Stock
our ability to grow our business, pursue acquisitions or improve our operating infrastructure and restrict our ability to compete in our markets
NewRisks Related to Ownership of Our Common Stock
We do not have any committed external source of funds or other support for our development and commercialization efforts, and we cannot be certain that additional funding will be available on acceptable terms, or at all

Dropped

DroppedRisks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates
multitude of factors, including, but not limited to, flaws in trial design, dose selection issues, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits
DroppedRisks Related to Our Reliance on Third Parties
clinical trials on a government-sponsored database, clinicaltrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions
DroppedRisks Related to Our Reliance on Third Parties
China, including as a result of the escalation of tariffs or other trade restrictions or if the BIOSECURE Act or a
DroppedRisks Related to Our Reliance on Third Parties
testing, storage, supply chain management or shipping. If we or any of our third-party manufacturers encounter such difficulties, our ability to supply material for clinical trials or any approved product could be delayed or stopped
DroppedRisks Related to Our Reliance on Third Parties
obtaining regulatory approval, we may receive less revenues than if we commercialized these products ourselves, which could materially harm our prospects
DroppedRisks Related to Our Business Operations and Industry
We expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
Preclinical generation and clinical trial enrollment hurdles.
DroppedRisks Related to Our Intellectual Property
therapeutic candidates, patents protecting the therapeutic candidates might expire before or shortly after such therapeutic candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours
DroppedRisks Related to Our Intellectual Property
its use for commercial purposes, we may be required to replace those software components, which could result in delays, additional cost and additional regulatory approvals
DroppedRisks Related to Ownership of Our Common Stock
our business. To the extent ESG matters negatively impact our reputation, it may also impede our ability to compete as effectively to attract and retain employees, which may adversely impact our operations
DroppedRisks Related to Ownership of Our Common Stock
Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or therapeutic candidates
DroppedRisks Related to Ownership of Our Common Stock
which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner
DroppedRisks Related to Ownership of Our Common Stock
Effective December 31, 2024, we no longer qualify as a "smaller reporting company" and, commencing with our Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2025, we may no longer take advantage of reduced disclosure and reporting requirements applicable to smaller reporting companies

Reworded

83% rewrittenRisks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates
Our therapeutic candidates are subject to extensive regulation and compliance, which is costly and time-consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our therapeutic candidates
Retitled and streamlined broad regulatory compliance risks for drug commercialization.
80% rewrittenRisks Related to Our Intellectual Property
Use of open source software could impose limitations on us that may adversely affect our business
Added specific consequences regarding delays, costs, and regulatory approvals if open source software components must be replaced.
79% rewrittenRisks Related to Our Business Operations and Industry
Legislation or other changes in U.S. tax law could adversely affect our business and financial condition
Updated to cite the OBBBA signed on July 4, 2025, and changed research expense capitalization rules to R&D performed outside the U.S.
77% rewrittenRisks Related to Ownership of Our Common Stock
We do not know whether an active, liquid and orderly trading market will be sustained for our common stock and as a result it may be difficult for our stockholders to sell their shares of our common stock
Updated to reflect that common stock is listed on the Nasdaq Global Market rather than noting the lack of a pre-IPO market.
Was: We do not know whether an active, liquid and orderly trading market will develop for our common stock and as a result it may be difficult for our stockholders to sell their shares of our common stock
75% rewrittenRisks Related to Our Intellectual Property
We, our collaborators and our service providers may be subject to a variety of privacy and data security laws and contractual obligations, which could increase compliance costs and our failure to comply with them could subject us to potentially significant fines or penalties and otherwise harm our business
Refined privacy and data security risk text regarding sensitive information and evolving global laws.
71% rewrittenRisks Related to Our Reliance on Third Parties
We are dependent on third-party vendors to provide certain licenses, products and services and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors
Maintained core third-party vendor supply and clinical trial disruption warnings.
68% rewrittenRisks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates
Substantial delays in the commencement, enrollment or completion of our planned clinical trials, or failure to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities could prevent us from commercializing any therapeutic candidates we determine to develop on a timely basis, if at all
Added the specific update that the ENTR-601-44 IND clinical hold was lifted in February 2025.
65% rewrittenRisks Related to Our Reliance on Third Parties
If conflicts arise between us and our current or potential collaborators, these parties may act in a manner adverse to us and could limit our ability to implement our strategies
Trimmed partner conflict text to remove duplicate wording on competing products.
64% rewrittenRisks Related to Ownership of Our Common Stock
Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities
62% rewrittenRisks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates
Furthermore, some of our competitors have ongoing clinical trials for therapeutic candidates that treat the same indications as our therapeutic candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors’ therapeutic candidates
58% rewrittenRisks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates
Our EEV therapeutic candidates are based on a novel therapeutic approach, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if at all
46% rewrittenRisks Related to Ownership of Our Common Stock
influential investors have increasingly focused on ESG practices and have placed increasing importance on the
45% rewrittenRisks Related to Ownership of Our Common Stock
Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our 2021 Plan and 2025 Inducement Equity Plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall
Was: Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our 2021 Plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall
43% rewrittenRisks Related to Commercialization of Our Therapeutic Candidates
We face significant competition, and if our competitors develop technologies or therapeutic candidates more rapidly than we do or their technologies are more effective, our business and our ability to develop and successfully commercialize products may be adversely affected
41% rewrittenRisks Related to Commercialization of Our Therapeutic Candidates
Even if we are able to commercialize any of our therapeutic candidates, if approved, such therapeutic candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business
38% rewrittenRisks Related to Our Business Operations and Industry
A pandemic, epidemic or outbreak of an infectious disease may materially and adversely affect our business and could cause a disruption to the development of our therapeutic candidates
37% rewrittenRisks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates
The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction
36% rewrittenRisks Related to Our Business Operations and Industry
Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our therapeutic candidates and decrease the prices we may obtain
32% rewrittenRisks Related to Ownership of Our Common Stock
Unstable market and global economic conditions, political instability and geopolitical events may have serious adverse consequences on our business, financial condition and stock price
Was: Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price
31% rewrittenRisks Related to Our Reliance on Third Parties
We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily
30% rewrittenRisks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates
We may not be successful in our efforts to expand our development portfolio of therapeutic candidates
26% rewrittenRisks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates
We may expend our limited resources to pursue particular therapeutic candidates or indications, such as our initial focuses on developing ENTR-601-44 and ENTR-601-45, and fail to capitalize on therapeutic candidates or indications that may be more profitable or for which there is a greater likelihood of success
Was: We may expend our limited resources to pursue a particular therapeutic candidate or indication, such as our initial focus on developing ENTR-601-44, and fail to capitalize on therapeutic candidates or indications that may be more profitable or for which there is a greater likelihood of success
24% rewrittenRisks Related to Our Intellectual Property
We may be subject to claims that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property
23% rewrittenRisks Related to Ownership of Our Common Stock
Anti-takeover provisions in our certificate of incorporation, our bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock
20% rewrittenRisks Related to Our Reliance on Third Parties
We may from time to time be dependent on single- or limited-source suppliers for some of the components and materials used in the therapeutic candidates we may develop

All 87 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

01We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue from product sales or become profitable or, if we achieve profitability, we may not be able to sustain it
02We will require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations
03Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance

Risks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates

04currently generate no revenue from sales of any product, and we may never be able to develop or commercialize a marketable productNew
05ENTR-601-51, ENTR-801 and our partnered candidate VX-670. Delay or failure to advance programs or modalities, including ENTR-601-44, ENTR-601-45, ENTR-601-50, ENTR-601-51, ENTR-801 and VX-670 could adversely impact our businessNew
06Our EEV therapeutic candidates are based on a novel therapeutic approach, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if at all58% rewritten
07trials and our therapeutic candidates may not have favorable results in clinical trials or receive regulatory approval on a timely basis, if at allNew
08Substantial delays in the commencement, enrollment or completion of our planned clinical trials, or failure to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities could prevent us from commercializing any therapeutic candidates we determine to develop on a timely basis, if at all68% rewritten
09Delays or difficulties in the enrollment of patients in clinical trials could delay or prevent our receipt of necessary regulatory approvals
10Furthermore, some of our competitors have ongoing clinical trials for therapeutic candidates that treat the same indications as our therapeutic candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors’ therapeutic candidates62% rewritten
11the perception that they are receiving placebo. Difficulty enrolling or maintaining a sufficient number of patients to conduct our clinical trials, may require us to delay, limit or terminate clinical trials, any of which would harm our business, financial condition, results of operations and prospectsNew
12Our therapeutic candidates are subject to extensive regulation and compliance, which is costly and time-consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our therapeutic candidates83% rewritten
13Neither we nor any current or future collaborator is permitted to market any of our therapeutic candidates in the United States until we receive approval from the FDANew
14Interim, topline and preliminary data from our preclinical studies and clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
15We may expend our limited resources to pursue particular therapeutic candidates or indications, such as our initial focuses on developing ENTR-601-44 and ENTR-601-45, and fail to capitalize on therapeutic candidates or indications that may be more profitable or for which there is a greater likelihood of success26% rewritten
16We may not be successful in our efforts to expand our development portfolio of therapeutic candidates30% rewritten
17Although we have obtained rare pediatric disease designation for ENTR-601-44, we may not be eligible to receive a priority review voucher in the event the FDA determines we no longer meet the criteria for designation, revokes the designation or FDA approval does not occur prior to September 30, 2029New
18The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction37% rewritten
19Changes in methods of therapeutic candidate manufacturing or formulation may result in additional costs or delay, which could adversely affect our business, results of operations and financial condition
20Clinical trial and product liability lawsuits against us could divert our resources, could cause us to incur substantial liabilities and could limit commercialization of any therapeutic candidates we may develop
21We may develop our current or future therapeutic candidates in combination with other therapies, which would expose us to additional risks

Risks Related to Our Reliance on Third Parties

22We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily31% rewritten
23We are dependent on third-party vendors to provide certain licenses, products and services and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors71% rewritten
24Due to the number of different programs, we may have cross contamination of products inside of our factories, CROs, suppliers, or in the clinic that affect the integrity of our therapeutics
25Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor or other third party will discover them or that our trade secrets will be misappropriated or disclosed
26We may from time to time be dependent on single- or limited-source suppliers for some of the components and materials used in the therapeutic candidates we may develop20% rewritten
27If conflicts arise between us and our current or potential collaborators, these parties may act in a manner adverse to us and could limit our ability to implement our strategies65% rewritten
28collaborations with us. Competing products, either developed by the collaborators or to which the collaborators have rights, may result in the withdrawal of support for our therapeutic candidatesNew
29If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans
30Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators

Risks Related to Commercialization of Our Therapeutic Candidates

31The commercial success of our therapeutic candidates will depend upon the degree of market acceptance of such therapeutic candidates by physicians, patients, healthcare payors and others in the medical community
32Even if we are able to commercialize any of our therapeutic candidates, if approved, such therapeutic candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business41% rewritten
33from list prices and are challenging the prices charged for products. We cannot be sure that coverage will be available for any therapeutic candidate that we commercialize and, if coverage is available, the level of reimbursementNew
34We face significant competition, and if our competitors develop technologies or therapeutic candidates more rapidly than we do or their technologies are more effective, our business and our ability to develop and successfully commercialize products may be adversely affected43% rewritten

Risks Related to Our Business Operations and Industry

35Our future success depends on our ability to retain key employees and to attract, retain and motivate qualified personnel
36Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our therapeutic candidates and decrease the prices we may obtain36% rewritten
37A pandemic, epidemic or outbreak of an infectious disease may materially and adversely affect our business and could cause a disruption to the development of our therapeutic candidates38% rewritten
38Failure to comply with environmental, health and safety laws and regulations could subject us to fines or penalties or incur costs that could harm our business
39property and entities that disposed or arranged for the disposal of hazardous substances may be held strictly, jointly and severally liable for the cost of investigating or remediating contamination caused by hazardous substance releases, even if they did not know of and were not responsible for the releases
40Our relationships with customers, third-party payors, physicians and healthcare providers will be subject to applicable anti-kickback, fraud and abuse, and other laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits
41Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
42We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management
43Legislation or other changes in U.S. tax law could adversely affect our business and financial condition79% rewritten
44December 31, 2025, we had U.S. federal net operating loss carryforwards of approximately $178.3 million, and our ability to utilize those net operating loss carryforwards could be limited by an “ownership change” as described above, which could result in increased tax liability to usNew
45The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our businessNew

Risks Related to Our Intellectual Property

46In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future therapeutic candidates
47We may not be able to protect our intellectual property rights throughout the world
48Issued patents covering any therapeutic candidates we may develop could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad
49Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
50Changes in patent law in the United States or worldwide could diminish the value of patents in general, thereby impairing our ability to protect any therapeutic candidates we may develop and our technology
51If we do not obtain patent term extension and data exclusivity for any therapeutic candidates we may develop, our business may be harmed
52We may be subject to claims challenging the inventorship or ownership of our patent and other intellectual property rights
53If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
54We may not be successful in obtaining necessary rights to any therapeutic candidate we may develop through acquisitions and in-licenses
55We may be subject to claims that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property24% rewritten
56Third-party claims of intellectual property infringement, misappropriation or other violations against us or our collaborators may prevent or delay the development and commercialization of our therapeutic programs and other proprietary technologies we may develop
57We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful
58If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
59Intellectual property rights do not necessarily address all potential threats
60The occurrence of any of these events would have a material adverse effect on our business, financial condition, results of operations and prospects
61We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development portfolio through acquisitions and in-licenses
62We, our collaborators and our service providers may be subject to a variety of privacy and data security laws and contractual obligations, which could increase compliance costs and our failure to comply with them could subject us to potentially significant fines or penalties and otherwise harm our business75% rewritten
63process personal sensitive data, conduct data protection assessments, transfer personal data to affiliates, and respond to consumer rights requestsNew
64been successful at curtailing state action on AI regulation, contributing to a complicated legislative patchwork, which may be litigated in state and federal courtsNew
65Use of open source software could impose limitations on us that may adversely affect our business80% rewritten
66Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor or other third party will discover our trade secrets or that our trade secrets will be misappropriated or disclosed
67Rights to improvements to our therapeutic candidates may be held by third parties
68We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers

Risks Related to Ownership of Our Common Stock

69We do not know whether an active, liquid and orderly trading market will be sustained for our common stock and as a result it may be difficult for our stockholders to sell their shares of our common stock77% rewritten
70our ability to grow our business, pursue acquisitions or improve our operating infrastructure and restrict our ability to compete in our marketsNew
71The market price of our common stock may be volatile, and investors could lose all or part of their investment
72If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline
73Increased attention to, and evolving expectations for, environmental, climate change, social, and governance (“ESG”) initiatives could increase our costs, harm our reputation, or otherwise adversely impact our business
74influential investors have increasingly focused on ESG practices and have placed increasing importance on the46% rewritten
75Unstable market and global economic conditions, political instability and geopolitical events may have serious adverse consequences on our business, financial condition and stock price32% rewritten
76Our business is affected by macroeconomic conditions, including rising inflation, tariffs, interest rates and supply chain constraints
77Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
78Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our 2021 Plan and 2025 Inducement Equity Plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall45% rewritten
79We do not have any committed external source of funds or other support for our development and commercialization efforts, and we cannot be certain that additional funding will be available on acceptable terms, or at allNew
80We are an “emerging growth company” and a smaller reporting company and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors
81We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock
82Anti-takeover provisions in our certificate of incorporation, our bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock23% rewritten
83Our Bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees
84We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to related compliance initiatives
85Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
86We may be subject to securities litigation, which is expensive and could divert management attention
87Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities64% rewritten

Other Entrada Therapeutics 10-Ks

FY2024 10-K risk factors
85 risks
Entrada Therapeutics faces substantial development and financing risks driven by its reliance on unapproved novel EEV technology and third-party manufacturers.
Filed Feb 27, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.